White House announces TrumpRx drug site and first Pfizer pricing deal

The White House on September 30, 2025 rolled out TrumpRx, a government-run site for buying prescription medicines at cash prices from drugmakers, and announced its first most-favored-nation pricing agreement, signed with Pfizer ^[3][4]. Most-favored-nation, or MFN, means U.S. prices are tied to what other wealthy countries pay ^[3].

The step followed an executive order signed May 12, 2025 that directed federal health officials to pursue MFN pricing and to set up direct-to-consumer purchasing programs, and letters sent July 31, 2025 to large manufacturers spelling out what they were expected to do ^[3][4]. "The United States is done subsidizing the health care of the rest of the world," Trump said at the announcement. "By taking this bold step, we're ending the era of global price gouging at the expense of American families" ^[4].

TrumpRx would not stock or ship medicine. A shopper would look up a drug on the site and then be sent to the manufacturer's own direct-to-consumer storefront to complete the purchase, officials said ^[4]. The discounted prices apply to people paying cash rather than using insurance ^[4]. Pfizer said many of its products and some specialty brands would cost about 50% less on average there than buying the same drugs without insurance ^[4]. Four Pfizer medicines were named as planned listings: Eucrisa, Duavee, Zavzpret and Xeljanz ^[3].

Pfizer also agreed to make nearly all of its products available to state Medicaid programs at MFN prices, pledged not to charge U.S. buyers more for new drugs than buyers in other developed countries, and said it would bring back increased foreign revenue tied to the administration's trade policies ^[3][4]. The company committed $70 billion to U.S. manufacturing and research and received a three-year exemption from pharmaceutical tariffs ^[4].

Officials said the site would arrive in "early 2026." As of October 1 it was not live, and its final design and features were still being settled; the White House declined to discuss website details the day after the rollout ^[3][4]. Early coverage questioned who would actually benefit: Axios reported that the roughly 92% of Americans with health insurance are unlikely to save much, since insured patients usually pay less through their plans than the cash price ^[4]. Medicaid already pays among the lowest drug prices, and most enrollees pay little or nothing out of pocket ^[4]. Investor Mark Cuban gave the program "a grade of B" based on what was public at the time ^[4]. Whether a cash-price marketplace changes what insured patients pay has not been established ^[3].

Why it matters for patients

For people taking semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), the September 30 news changed nothing on its own. No GLP-1 drug was among Pfizer's named listings ^[3][4]. The importance was structural: the direct-to-consumer channel announced that day became the mechanism the GLP-1 manufacturers later agreed to use ^[1][2].

It also drew a line worth understanding. TrumpRx pricing is a cash option, not an insurance benefit, and insurance terms — Medicare and Medicaid coverage — were handled through separate provisions in the later manufacturer agreements ^[1][2][4].

What happens next

TrumpRx's target was early 2026, with details unresolved as of October 1, 2025 ^[3][4].

Five weeks after the Pfizer deal, on November 6, 2025, the White House announced agreements with Eli Lilly and Novo Nordisk that did cover GLP-1s ^[1][2]. Monthly prices listed for Ozempic and Wegovy were set to fall from about $1,000 and $1,350 to $350 through TrumpRx; Zepbound and orforglipron, if approved, from $1,086 to an average of $346 ^[1][2]. A first dose of any future FDA-approved oral GLP-1 from either company was pegged at $150 per month ^[1][2]. The Medicare and state Medicaid price for Ozempic, Wegovy, Mounjaro and Zepbound was put at $245, with a $50 monthly Medicare co-pay, and Medicare was to cover Wegovy and Zepbound for obesity with related conditions for the first time ^[1][2]. Novo Nordisk added $10 billion in planned U.S. manufacturing investment, while Lilly has announced at least $27 billion ^[2]. Under Lilly's separate self-pay pharmacy channel, a Zepbound multi-dose pen, if approved, was set at $299 for the lowest dose and up to $449 for the highest ^[1].

Semaglutide had earlier been selected on January 17, 2025 for the second round of Medicare price negotiations under the Inflation Reduction Act ^[1]. Novo Nordisk was also expected to receive a three-year exemption from tariffs under its agreement ^[1].